Tsushima T
Department of Urology, Okayama University Medical School.
Nihon Rinsho. 1998 Aug;56(8):2167-72.
Chemotherapy may be an appropriate treatment for patients with evidence of disease progression despite of antiandrogen withdrawal or secondary hormonal therapy. But none of the chemotherapeutic regimens, neither monotherapy nor combination therapy, were shown to be superior to another with regard to survival. The criteria to assess the effect of chemotherapy on disease-related symptoms and quality of life is expected to be framed. Preclinical investigations and well-designed, well-powered clinical trials remain key to altering the natural history of hormone-refractory prostate cancer.
对于尽管停用抗雄激素或接受二线激素治疗仍有疾病进展证据的患者，化疗可能是一种合适的治疗方法。但在生存方面，没有一种化疗方案，无论是单药治疗还是联合治疗，被证明优于另一种。预计将制定评估化疗对疾病相关症状和生活质量影响的标准。临床前研究以及设计良好、样本量充足的临床试验仍然是改变激素难治性前列腺癌自然病程的关键。
